1. In Vivo
  2. >>Business Strategy

No Surprise: LifeScan is Probably Buying Inverness

LifeScan is negotiating to buy Inverness Medical Technology, its long-time contract manufacturer, which makes electrochemical-based glucose meters and strips. LifeScan recently introduced a new glucose meter designed and made by Inverness; response to the product has been good and LifeScan wants more control of its partner, especially its manufacturing operations. LifeScan sees the Inverness technology as a key to its strategy for regaining its number one position in the lucrative glucose testing market. Inverness, for its part, has been primping itself to be bought by LifeScan for years. The parties are in final negotiations.

Johnson & Johnson has finally done what everyone thought it should do and wondered why it hadn't done earlier—made an offer to buy Inverness Medical Technology Inc. [See Deal] Inverness already supplies J&J's LifeScan Inc. subsidiary with an electrochemical detection blood glucose meter and strip that is key to its comeback play in diabetes monitoring. For much of the parties' six-year relationship, Inverness has been primping, hoping for a moment like this. LifeScan hasn't committed until now, even though it has become increasingly reliant on Inverness.

But LifeScan is at a crossroads. Early this year it launched One Touch Ultra, a new meter made by Inverness...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.